Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 8-K (Current Report)
Report Date: April 27, 2026
Event: The Company held an Extraordinary General Meeting where shareholders approved an amendment to extend the deadline to consummate a business combination. The extension allows for up to 12 one-month extensions from the original termination date of April 29, 2026, to April 29, 2027, contingent upon sponsor deposits into the Trust Account.
Key Financial Metrics and Liquidity
Trust Account Redemption:
- Shares Redeemed: 9,440,230 ordinary shares.
- Total Redemption Amount: $99,336,016.67.
- Redemption Price: Approximately $10.52 per share.
Capital Structure Post-Redemption:
- Outstanding Ordinary Shares: 24,276,913.
- Shares from Initial Public Offering: 13,559,770.
Extension Funding Requirement: The sponsor must deposit the lesser of $300,000 or $0.04 per non-redeemed public share for each one-month extension period into the Trust Account.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or debt levels, as the Company is a Special Purpose Acquisition Company (SPAC) in the pre-combination phase.
Material Changes Versus Prior Period
Extension of Combination Period: The Company's charter was amended to extend the deadline for a business combination from April 29, 2026, to April 29, 2027 (subject to monthly sponsor funding).
Share Count Reduction: Following the redemption of 9,440,230 shares, the total outstanding share count decreased from 33,517,143 (record date) to 24,276,913.
Trust Account Balance: Approximately $99.3 million was removed from the Trust Account to satisfy redemption requests.
Guidance, Outlook, and Management Commentary
Management Action: The Board of Directors has approved an initial one-month extension of the term to May 29, 2026.
Voting Results:
- Extension Proposal: Approved by special resolution.
- Votes For: 18,906,281.
- Votes Against: 4,892,646.
- Abstain: 0.
- Adjournment Proposal: Not presented as sufficient votes were obtained for the Extension Proposal.
Quorum: 23,798,927 shares were voted, representing approximately 70.58% of shares entitled to vote.
Investor Verification Checklist
- Verify the current balance of the Trust Account following the $99.3 million redemption.
- Confirm the sponsor's ability and commitment to fund the $0.04 per share (or $300,000 cap) monthly extension payments.
- Review the updated number of public shares outstanding (24,276,913) for dilution calculations in future merger scenarios.
- Monitor the Company's progress toward identifying a target business combination before the new deadline of April 29, 2027.